Condition: FIGO Stage III and IV Ovarian Cancer · Fallopian Tube Cancers · Primary Peritoneal Cancer · Sponsor: TORL Biotherapeutics, LLC
A Phase 1B/2 Study to Investigate the Safety and Efficacy of TORL-1-23 with Chemotherapy Given Before Initial Surgery in Women with Advanced Stage Ovarian Cancer
This description comes directly from the study's public registry record.
Caroline Labib, PharmD · 310-348-9636 · caroline.labib@torlbio.com
Always discuss trial participation with your own doctor first.
| Providence St. Jude Medical Center | Fullerton, California, United States | Recruiting |
| City of Hope | Irvine, California, United States | Recruiting |
| University of Southern California | Los Angeles, California, United States | Recruiting |
| UCLA | Los Angeles, California, United States | Recruiting |
| The Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Mt Sinai Hospital | New York, New York, United States | Recruiting |
| Duke University | Durham, North Carolina, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07322094